FDA
-
-
-
-
-
-
-
Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
-
-
-
-
-
-
-
OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones
-
-
-
-
-
-
-
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
-
-
-
-
-
-
-
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
-
-
-
324,852 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

